(CYRX) Cryoport - Overview
Sector: Industrials | Industry: Integrated Freight & Logistics | Exchange: NASDAQ (USA) | Market Cap: 706m USD | Total Return: 132.5% in 12m
Avg Turnover: 6.32M
Qual. Beats: 0
Rev. Trend: -86.3%
Qual. Beats: 0
Warnings
High Debt/EBITDA (18.3) with thin interest coverage (-15.2)
High Debt while negative Cash Flow
Interest Coverage Ratio -15.2 is critical
Altman Z'' -3.93 < 1.0 - financial distress zone
Tailwinds
Supp Ema20, Rs Leader, Idiosyncratic Leader
Cryoport, Inc. (CYRX) provides comprehensive temperature-controlled supply chain solutions for the biopharma, animal health, and reproductive medicine markets. The company operates through two primary segments: Life Sciences Services, which manages logistics, biostorage, and cryopreservation, and Life Sciences Products, which manufactures cryogenic freezers and monitoring systems. Its portfolio includes specialized shipping systems, IoT-based monitoring solutions, and consulting services for apheresis collection and cryo-process optimization.
The business model relies on a highly specialized cold chain infrastructure designed to support the commercialization of cell and gene therapies, which often require strictly maintained cryogenic temperatures to ensure product efficacy. As clinical trial volumes for advanced therapies increase, the demand for integrated logistics that combine hardware manufacturing with real-time monitoring and bioservices continues to grow. Investors looking for deeper fundamental analysis may find further insights on ValueRay.
Founded in 1999 and headquartered in Brentwood, Tennessee, Cryoport utilizes both direct sales and distribution networks to deliver its equipment and services globally. By integrating hardware like the MVE Fusion freezer with software platforms for sample tracking and drug product release, the company aims to provide an end-to-end solution for high-value biological specimens.
- Expansion of cell and gene therapy clinical trials drives logistics service revenue
- Global biopharma R&D spending volatility impacts life sciences products segment demand
- Shift from capital equipment purchases to leasing models affects short-term margins
- Regulatory approval of high-volume commercial therapies increases recurring specialized shipping volume
- High interest rates and financing costs constrain biotech customer equipment investment budgets
| Net Income: 77.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 1.76 > 1.0 |
| NWC/Revenue: 134.3% < 20% (prev 171.2%; Δ -36.95% < -1%) |
| CFO/TA -0.00 > 3% & CFO -503k > Net Income 77.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago -0.10% < -2% |
| Gross Margin: 47.19% > 18% (prev 0.45%; Δ 4.67k% > 0.5%) |
| Asset Turnover: 25.00% > 50% (prev 28.14%; Δ -3.14% > 0%) |
| Interest Coverage Ratio: -15.17 > 6 (EBITDA TTM -7.05m / Interest Expense TTM 2.21m) |
| A: 0.32 (Total Current Assets 470.5m - Total Current Liabilities 224.9m) / Total Assets 763.6m |
| B: -0.92 (Retained Earnings -699.4m / Total Assets 763.6m) |
| C: -0.05 (EBIT TTM -33.5m / Avg Total Assets 731.7m) |
| D: -2.62 (Book Value of Equity -702.6m / Total Liabilities 268.6m) |
| Altman-Z'' = -3.93 = D |
| DSRI: 1.48 (Receivables 39.0m/28.4m, Revenue 182.9m/196.9m) |
| GMI: 0.96 (GM 47.19% / 45.17%) |
| AQI: 0.89 (AQ_t 0.21 / AQ_t-1 0.24) |
| SGI: 0.93 (Revenue 182.9m / 196.9m) |
| TATA: 0.10 (NI 77.2m - CFO -503k) / TA 763.6m) |
| Beneish M = -2.68 (Cap -4..+1) = A |
As of May 28, 2026, the stock is trading at USD 14.02 with a total of 357,974 shares traded.
Over the past week, the price has changed by +7.60%,
over one month by +35.07%,
over three months by +66.51% and
over the past year by +132.50%.
Cryoport has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CYRX.
- StrongBuy: 4
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.8 | 5.4% |
P/E Forward = 82.6446
P/S = 3.8573
P/B = 1.5667
P/EG = 62.1277
Revenue TTM = 182.9m USD
EBIT TTM = -33.5m USD
EBITDA TTM = -7.05m USD
Long Term Debt = 1.03m USD (from longTermDebt, last quarter)
Short Term Debt = 189.6m USD (from shortTermDebt, last quarter)
Debt = 274.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 43.9m
Net Debt = -129.2m USD (calculated: Debt 274.4m - CCE 403.6m)
Enterprise Value = 576.9m USD (706.1m + Debt 274.4m - CCE 403.6m)
Interest Coverage Ratio = -15.17 (Ebit TTM -33.5m / Interest Expense TTM 2.21m)
EV/FCF = -23.98x (Enterprise Value 576.9m / FCF TTM -24.1m)
FCF Yield = -4.17% (FCF TTM -24.1m / Enterprise Value 576.9m)
FCF Margin = -13.15% (FCF TTM -24.1m / Revenue TTM 182.9m)
Net Margin = 42.18% (Net Income TTM 77.2m / Revenue TTM 182.9m)
Gross Margin = 47.19% ((Revenue TTM 182.9m - Cost of Revenue TTM 96.6m) / Revenue TTM)
Gross Margin QoQ = 45.85% (prev 47.77%)
Tobins Q-Ratio = 0.76 (Enterprise Value 576.9m / Total Assets 763.6m)
Interest Expense / Debt = 0.81% (Interest Expense 2.21m / Debt 274.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -26.5m (EBIT -33.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.09 (Total Current Assets 470.5m / Total Current Liabilities 224.9m)
Debt / Equity = 0.55 (Debt 274.4m / totalStockholderEquity, last quarter 495.0m)
Debt / EBITDA = 18.33 (negative EBITDA) (Net Debt -129.2m / EBITDA -7.05m)
Debt / FCF = 5.37 (negative FCF - burning cash) (Net Debt -129.2m / FCF TTM -24.1m)
Total Stockholder Equity = 477.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.55% (Net Income 77.2m / Total Assets 763.6m)
RoE = 6.56% (Net Income TTM 77.2m / Total Stockholder Equity 1.18b)
RoCE = -2.85% (EBIT -33.5m / Capital Employed (Equity 1.18b + L.T.Debt 1.03m))
RoIC = -8.15% (negative operating profit) (NOPAT -26.5m / Invested Capital 324.7m)
WACC = 8.21% (E(706.1m)/V(980.5m) * Re(11.15%) + D(274.4m)/V(980.5m) * Rd(0.81%) * (1-Tc(0.21)))
Discount Rate = 11.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 0.84%
[DCF] Fair Price = unknown (Cash Flow -24.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -86.32 | Revenue CAGR: -9.45% | SUE: 0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.18 | Chg30d=-7.82% | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.16 | Chg30d=-8.87% | Revisions=+20% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.73 | Chg30d=-12.82% | Revisions=-14% | GrowthEPS=-8.1% | GrowthRev=+10.3%
EPS next Year (2027-12-31): EPS=-0.62 | Chg30d=-8.77% | Revisions=+33% | GrowthEPS=+15.4% | GrowthRev=+9.6%
[Analyst] Revisions Ratio: +33%